FDA Approves Auvelity, Faster-Acting Antidepressant - Verywell …
2022年10月11日 · The FDA has approved Auvelity, a new antidepressant that may treat symptoms faster than other medications. The drug may be especially effective for individuals with treatment-resistant depression. Auvelity joins ketamine as a potential new wave of faster-acting antidepressants.
Experimental depression treatment is nearly 80% effective in …
2021年10月28日 · A new type of magnetic brain stimulation brought rapid remission to almost 80% of participants with severe depression in a study conducted at the Stanford University School of Medicine. The treatment, known as Stanford accelerated intelligent neuromodulation therapy (SAINT) or simply Stanford neuromodulation therapy, is an intensive ...
Newest Antidepressants: Brexanolone, Esketamine, Agomelatine - Healthline
2022年9月5日 · In 2019, the Food and Drug Administration (FDA) approved two new antidepressants, brexanolone and esketamine. There’s also been renewed interest in agomelatine, an antidepressant not currently...
New Antidepressant Exxua (Geriprone) Is Coming in 2024
2024年3月4日 · Exxua represents a promising new antidepressant for Major Depressive Disorder (MDD) with a unique mechanism of action targeting the glutamatergic system. The drug gained FDA approval after years of research involving more than 5,000 patients.
New Treatment for Clinical Depression Auvelity Approved by FDA
2022年8月23日 · Auvelity is a new, fast-acting drug used to treat major depressive disorder or clinical depression. It is the first pill in more than 60 years with a new action to treat the condition.
FDA Approves First, Only NMDA Receptor Antagonist for Major …
2022年8月19日 · Auvelity uses the first new oral mechanism of action for major depressive disorder developed in more than 60 years, according to an Axsome press release. It works on the NMDA receptor, an ionotropic glutamate receptor, and on the sigma-1 receptor in the brain via its dextromethorphan component.
New Hope for Rapid-Acting Depression Treatment - NIMH
2024年10月24日 · A new study, funded in part by the National Institute of Mental Health, showed that a new medication derived from ketamine is safe and acceptable for use in humans, setting the stage for clinical trials testing it for hard-to-treat mental disorders like severe depression.
FDA clears first digital treatment for depression, but experts ... - CNN
2024年4月2日 · Rejoyn is a smartphone app intended for use alongside antidepressant medications for people 22 and older who have a diagnosis of major depressive disorder. The US Food and Drug Administration...
New Antidepressants: What Are They and More I Psych Central
2023年7月26日 · Three new antidepressants are on the market to treat depression: Unlike SSRIs and other antidepressants, these newer medications can start relieving symptoms in a few hours or days instead of...
New Drug for Major Depression Is Approved by FDA
2023年10月3日 · The U.S. Food and Drug Administration (FDA) has approved gepirone ER, sold under the brand name Exxua, a first-in-class medication for the treatment of major depressive disorder (MDD),...